Dr. Noon CVD

Mediwhale is a Seoul-based medical AI company that uses retinal images to assess systemic and eye disease risk. It aims to make cardiovascular risk screening as simple as an eye photo, instead of relying on CT scans or blood-based scores that are costly or hard to scale.

Dr. Noon CVD analyzes retinal photographs taken with a standard fundus camera: staff capture the images in under three minutes, upload them to the institution's server or a cloud platform, and the AI instantly returns a report estimating future cardiovascular disease risk. The underlying Reti-CVD biomarker was validated in a pivotal trial and against coronary artery calcium scoring. A companion product, Dr. Noon Fundus, detects glaucoma, cataract and retinal diseases from a single photo. Customers are clinics, hospitals and health screening centers.

• Retinal cardiovascular risk: estimates future cardiovascular disease risk from fundus photographs.
• Fast workflow: image capture under three minutes with instant AI results and an auto-generated report.
• Flexible hosting: images are analyzed on the institution's server or on a cloud platform.
• Eye disease screening: Dr. Noon Fundus detects glaucoma, cataract and retinal diseases from one photo.
• Clinical evidence: validated in a pivotal Reti-CVD trial and with UK Biobank data.
• Regulatory coverage: MFDS licensed, CE certified and approved in nine regions according to the company.

Private health check-up centers in Vietnam could add a retinal cardiovascular risk test to executive and corporate packages. Diabetes and endocrinology clinics could screen patients for both eye disease and heart risk in one visit. Eye hospital chains could offer cardiovascular risk reports as a new service line linked to cardiology referrals.

Adds cardiovascular risk stratification to a routine eye photo without radiation, blood draws or extra specialist time. Needs only a fundus camera and minimal operator training, so it fits check-up centers and primary care. Returns results instantly after an image capture of under three minutes. Company-reported accuracy is comparable to heart CT and coronary calcium scoring, which supports referral decisions.

Cardiovascular disease is a major cause of death in Southeast Asia, while access to cardiac CT and specialists is limited outside major cities. Health check-up packages are growing in Vietnam's private sector, and non-invasive AI screening that reuses existing fundus cameras matches the regional push for early detection of chronic disease.

Mediwhale is headquartered at 746 Nonhyeon-ro, Gangnam District, Seoul. Dr. Noon CVD holds Korean MFDS license 22-513 and a CE certificate issued by SGS Belgium, and received CE MDR certification in May 2026. Products are available in Korea, Dubai, the UK and Italy; customers include GluCare.Health and Naeun Hospital. Awards include the 2023 CES Innovation Award and NextRise 2025 Top Innovator.